# Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

> **NCT07400952** · PHASE2 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 100 (estimated)

## Conditions studied

- Keratoconus

## Interventions

- **DRUG:** GLK-221 Ophthalmic Solution
- **DRUG:** Placebo Ophthalmic Solution

## Key facts

- **NCT ID:** NCT07400952
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400952, "Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07400952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*